Vipivotide tetraxetan Ligand-Linker Conjugate

Vipivotide tetraxetan Ligand-Linker Conjugate

• CAS Number: 1703768-74-4
• UNSPSC Description: Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA)[1].
• Target Antigen: ADC Linker
• Type: ADC Related
• Related Pathways: Antibody-drug Conjugate/ADC Related
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/vipivotide-tetraxetan-linker.html
• Purity: 99.95
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CN)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O
• Molecular Weight: 655.74
• References & Citations: [1]Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported